A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
A phase 2 trial of Zanidatamab, Paclitaxel / nab-paclitaxel, Docetaxel in her2-positive breast cancer, run by Jazz Pharmaceuticals, now recruiting.
Overview
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer is a phase 2 interventional study registered as NCT07102381 by Jazz Pharmaceuticals, with 125 participants planned, started 2025-09-24 and due to reach its primary completion in 2028-01-01. Interventions recorded: Zanidatamab, Paclitaxel, Docetaxel, Carboplatin, Trastuzumab. Conditions listed: HER2-positive Breast Cancer, Breast Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Shares Pertuzumab, Docetaxel, Trastuzumab, Carboplatin.
- TrialA Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Brea
Shares Pertuzumab, Docetaxel, Trastuzumab, Carboplatin.
- TrialA Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Pertuzumab, Docetaxel, Trastuzumab, HER2-positive breast cancer.
- TrialA Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or M
Shares Pertuzumab, Docetaxel, Trastuzumab, HER2-positive breast cancer.
- TrialA Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o
Shares Zanidatamab, Jazz Pharmaceuticals, Trastuzumab, HER2-positive breast cancer.
- TrialHER2CLIMB-05
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.
- TrialStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.
- TrialA Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive
Shares Pertuzumab, Docetaxel, HER2-positive breast cancer.